The Life Sciences team advised Concert Pharmaceuticals on its underwritten public offering of 10,000,000 shares of its common stock to the public at $4.75 per share. The aggregate gross proceeds to Concert from this offering were $47.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Concert. Concert also announced the underwriters’ exercise in full of their option to purchase an additional 1,500,000 shares of common stock in the public offering at the public offering price, as well as the receipt of $18.9 million upon the exercise of tranche 1 warrants to purchase 3,981 shares of Series X1 Preferred Stock issued to BVF Partners L.P. and RA Capital Management in November 2021. Through the public offering and warrant exercise, Concert raised aggregate gross proceeds of $73.5 million.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform).
The Goodwin team was led by Sarah Ashfaq, John Mutkoski, Della Fok and Larissa Pinho (Corporate), Susan Lee, Elizabeth Mulkey and Joe Thomas (Regulatory/FDA), Janet Andolina and Chris Zhao (Tax), Ettore Santucci (Opinions), with invaluable assistance from Peter LaVigne with FINRA matters.